Citations (77)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (21)
Anna Asklid, Maria Winqvist, Sandra Eketorp Sylvan, Agnes Mattsson, Einar Björgvinsson, Frans Søltoft, Johanna Repits, Joris Diels, Anders Österborg & Lotta Hansson. (2017) Outcomes of second-line treatment in chronic lymphocytic leukemia – a population-based study from a well defined geographical region between 2003 and 2013. Leukemia & Lymphoma 58:5, pages 1219-1223.
Read now
Read now
Ryan W Jacobs, Farrukh T Awan, Lori A Leslie, Saad Z Usmani & Nilanjan Ghosh. (2016) The shrinking role of chemotherapy in the treatment of chronic lymphocytic leukemia. Expert Review of Hematology 9:12, pages 1177-1187.
Read now
Read now
Anders Österborg, Miklós Udvardy, Andrey Zaritskey, Per-Ola Andersson, Sebastian Grosicki, Grzegorz Mazur, Polina Kaplan, Michael Steurer, Anna Schuh, Marco Montillo, Iryna Kryachok, Jan Moritz Middeke, Yaroslav Kulyaba, Grygoriy Rekhtman, Michele Gorczyca, Siobhan Daly, Chai-Ni Chang, Steen Lisby & Ira Gupta. (2016) Phase III, randomized study of ofatumumab versus physicians’ choice of therapy and standard versus extended-length ofatumumab in patients with bulky fludarabine-refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 57:9, pages 2037-2046.
Read now
Read now
Clemens M. Wendtner, Michael Hallek, Graeme A. M. Fraser, Anne-Sophie Michallet, Peter Hillmen, Jan Dürig, Matt Kalaycio, John G. Gribben, Stephan Stilgenbauer, Andreas Buhler, Thomas J. Kipps, Brendan Purse, Jennie Zhang, Sabine De Bedout, Jay Mei & Asher Chanan-Khan. (2016) Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*. Leukemia & Lymphoma 57:6, pages 1291-1299.
Read now
Read now
Anna Maria Frustaci, Alessandra Tedeschi, Paola Picardi, Roberto Cairoli & Marco Montillo. (2015) Clinical utility and patient considerations in the use of ofatumumab in chronic lymphocytic leukemia. Biologics: Targets and Therapy 9, pages 75-86.
Read now
Read now
Racquel D. Innis-Shelton, Randall S. Davis, Lawrence Lamb & Shin Mineishi. (2015) Paradigm shifts in the management of poor-risk chronic lymphocytic leukemia. Leukemia & Lymphoma 56:6, pages 1626-1635.
Read now
Read now
Sebastian Grosicki. (2015) Ofatumumab for the treatment of chronic lymphocytic leukemia. Expert Review of Hematology 8:3, pages 265-272.
Read now
Read now
Constantine S. Tam & Stephan Stilgenbauer. (2015) How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation?. Leukemia & Lymphoma 56:3, pages 587-593.
Read now
Read now
Sandra Eketorp Sylvan, Lotta Hansson, Claes Karlsson, Stefan Norin, Jeanette Lundin & Anders Österborg. (2014) Outcomes of patients with fludarabine-refractory chronic lymphocytic leukemia: a population-based study from a well-defined geographic region. Leukemia & Lymphoma 55:8, pages 1774-1780.
Read now
Read now
Mohammed ZH Farooqui & Adrian Wiestner. (2013)
Ibrutinib for the treatment of chronic lymphocytic leukemia. Expert Opinion on Orphan Drugs 1:11, pages 925-933.
Read now
Read now
Constantine S. Tam & Michael J. Keating. (2013) Selection of rituximab dosage in chronic lymphocytic leukemia: where is the evidence?. Leukemia & Lymphoma 54:5, pages 934-939.
Read now
Read now
Clemens-Martin Wendtner, Peter Hillmen, Daruka Mahadevan, Andreas Bühler, Lutz Uharek, Steven Coutré, Olga Frankfurt, Adrian Bloor, Francesc Bosch, Richard R. Furman, Eva Kimby, John G. Gribben, Marco Gobbi, Luke Dreisbach, David D. Hurd, Mikkael A. Sekeres, Alessandra Ferrajoli, Sheetal Shah, Jennie Zhang, Laure Moutouh-de Parseval, Michael Hallek, Nyla A. Heerema, Stephan Stilgenbauer & Asher A. Chanan-Khan. (2012) Final results of a multicenter phase 1 study of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 53:3, pages 417-423.
Read now
Read now
Leslie A Andritsos & Michael R Grever. (2011) Salvage therapy for relapsed chronic lymphocytic leukemia. Expert Review of Hematology 4:2, pages 199-212.
Read now
Read now
John L Reagan & Jorge J Castillo. (2011) Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia. Expert Review of Anticancer Therapy 11:2, pages 151-160.
Read now
Read now
Jorge Castillo & Kimberly Perez. (2010) The role of ofatumumab in the treatment of chronic lymphocytic leukemia resistant to previous therapies. Journal of Blood Medicine 1, pages 1-8.
Read now
Read now
Ali Bazargan & Constantine S. Tam. (2010) New angles of attack in the fight against chronic lymphocytic leukemia: the advent of novel non-chemotherapeutic agents. Leukemia & Lymphoma 51:9, pages 1596-1611.
Read now
Read now
Apostolia-Maria Tsimberidou & Michael J. Keating. (2010) Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options. Leukemia & Lymphoma 51:7, pages 1188-1199.
Read now
Read now
Myron S. Czuczman & Stephanie A. Gregory. (2010) The future of CD20 monoclonal antibody therapy in B-cell malignancies. Leukemia & Lymphoma 51:6, pages 983-994.
Read now
Read now
Anders Österborg. (2010) Ofatumumab, a human anti-CD20 monoclonal antibody. Expert Opinion on Biological Therapy 10:3, pages 439-449.
Read now
Read now
Richard R. Furman, Andres Forero-Torres, Andrei Shustov & Jonathan G. Drachman. (2010) A phase I study of dacetuzumab (SGN-40, a humanized anti-CD40 monoclonal antibody) in patients with chronic lymphocytic leukemia. Leukemia & Lymphoma 51:2, pages 228-235.
Read now
Read now
Stephen P. Mulligan. (2007) Chronic lymphocytic leukaemia resistant to both fludarabine and alemtuzumab – Double jeopardy. Leukemia & Lymphoma 48:10, pages 1885-1887.
Read now
Read now
Articles from other publishers (56)
Constantine S. Tam. (2021) Upfront therapy: the case for continuous treatment. Hematology 2021:1, pages 55-58.
Crossref
Crossref
Kristina Tomić, Teodora Karan-Đurašević, Vojin Vuković, Biljana Mihaljević & Darko Antić. (2020) Clinical significance of TP53 aberrations and IGHV mutational status in chronic lymphocytic leukemia. Medicinski podmladak 71:4, pages 47-53.
Crossref
Crossref
Mary Ann Anderson, Andrew W. Roberts & John F. Seymour. 2018. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas. Resistance of Targeted Therapies Excluding Antibodies for Lymphomas
23
43
.
Anthony J. Hatswell, Gwilym J. Thompson, Penny A. Maroudas, Oleg Sofrygin & Thomas E. Delea. (2017) Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia. Cost Effectiveness and Resource Allocation 15:1.
Crossref
Crossref
L.A. Butler, C.S. Tam & J.F. Seymour. (2017) Dancing partners at the ball: Rational selection of next generation anti-CD20 antibodies for combination therapy of chronic lymphocytic leukemia in the novel agents era. Blood Reviews 31:5, pages 318-327.
Crossref
Crossref
Lijian Yu, Haesook T. Kim, Siddha N. Kasar, Parul Benien, Wei Du, Kevin Hoang, Andrew Aw, Bethany Tesar, Reina Improgo, Stacey M. Fernandes, Saranya Radhakrishnan, Josephine L. Klitgaard, Charles Lee, Gad Getz, Sunita R. Setlur & Jennifer R. Brown. (2017) Survival of Del17p CLL Depends on Genomic Complexity and Somatic Mutation. Clinical Cancer Research 23:3, pages 735-745.
Crossref
Crossref
Maria Winqvist, Fariba Mozaffari, Marzia Palma, Sandra Eketorp Sylvan, Lotta Hansson, Håkan Mellstedt, Anders Österborg & Jeanette Lundin. (2016) Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints. Cancer Immunology, Immunotherapy 66:1, pages 91-102.
Crossref
Crossref
Crescenzio Francesco Minervini, Cosimo Cumbo, Paola Orsini, Claudia Brunetti, Luisa Anelli, Antonella Zagaria, Angela Minervini, Paola Casieri, Nicoletta Coccaro, Giuseppina Tota, Luciana Impera, Annamaria Giordano, Giorgina Specchia & Francesco Albano. (2016) TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing. Diagnostic Pathology 11:1.
Crossref
Crossref
David J. M. Routledge & Adrian J. C. Bloor. (2016) Recent advances in therapy of chronic lymphocytic leukaemia. British Journal of Haematology 174:3, pages 351-367.
Crossref
Crossref
Sandra Eketorp Sylvan, Henriette Skribek, Stefan Norin, Orsolya Muhari, Anders Österborg & Laszlo Szekely. (2016) Sensitivity of chronic lymphocytic leukemia cells to small targeted therapeutic molecules: An in vitro comparative study. Experimental Hematology 44:1, pages 38-49.e1.
Crossref
Crossref
Eric Durot, Anne-Sophie Michallet, Stéphane Leprêtre, Quoc-Hung Le, Véronique Leblond & Alain Delmer. (2015) Platinum and high-dose cytarabine-based regimens are efficient in ultra high/high-risk chronic lymphocytic leukemia and Richter's syndrome: results of a French retrospective multicenter study. European Journal of Haematology 95:2, pages 160-167.
Crossref
Crossref
Anders Österborg, William G. Wierda, Jiří Mayer, Georg Hess, Peter Hillmen, Johannes Schetelig, Anna Schuh, Lukáš Smolej, Christian Beck, Brigitte Dreyfus, Andrzej Hellman, Piotr Kozlowski, Michael Pfreundschuh, Rita Rizzi, Martin Spacek, Jennifer L. Phillips, Ira V. Gupta, Vanessa Williams, Roxanne C. Jewell, Noelia Nebot, Steen Lisby & Martin J. S. Dyer. (2015) Ofatumumab retreatment and maintenance in fludarabine-refractory chronic lymphocytic leukaemia patients. British Journal of Haematology 170:1, pages 40-49.
Crossref
Crossref
Carlos Cuesta-Mateos, Javier Loscertales, Anna Kreutzman, Beatriz Colom-Fernández, Itxaso Portero-Sáinz, Juan José Pérez-Villar, Fernando Terrón & Cecilia Muñoz-Calleja. (2015) Preclinical activity of anti-CCR7 immunotherapy in patients with high-risk chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy 64:6, pages 665-676.
Crossref
Crossref
Adrian Bloor, Erwin De Cock, Anthony J Hatswell, Radek Wasiak, Jamie Elvidge, Ceilidh Stapelkamp, Tsveta Hadjivassileva, Amin Haiderali & Julio Delgado. (2015) Survival outcomes and treatment costs for patients with double-refractory chronic lymphocytic leukaemia (DR-CLL). British Journal of Haematology 169:3, pages 449-452.
Crossref
Crossref
Lucie Oberic, Willy Vaillant, Benjamin Hebraud, Christian Recher, Etienne Suc, Philippe Houyau, Guy Laurent & Loic Ysebaert. (2015) Clinical activity of a new regimen combining gemcitabine and alemtuzumab in high-risk relapsed/refractory chronic lymphocytic leukemia patients. European Journal of Haematology 94:1, pages 37-42.
Crossref
Crossref
S. Eketorp Sylvan, J. Lundin, M. Ipek, M. Palma, C. Karlsson & L. Hansson. (2014) Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL)—a single region experience on consecutive patients. Annals of Hematology 93:10, pages 1725-1733.
Crossref
Crossref
Margaret A. Lindorfer, Joost M. Bakker, Paul W.H.I. Parren & Ronald P. Taylor. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
1733
1774
.
Rohtesh S. Mehta, Antonio Di Stasi, Chitra Hosing, Nina Shah, Katayoun Rezvani, Amin Alousi, Susan O'Brien, William Wierda, Michael Keating & Elizabeth J. Shpall. (2014) Lenalidomide-Induced Graft-Vs.-Leukemia Effect in a Patient With Chronic Lymphocytic Leukemia Who Relapsed After Allogeneic Stem Cell Transplant. Clinical Lymphoma Myeloma and Leukemia 14:3, pages e105-e109.
Crossref
Crossref
Antonio Cuneo, Francesco Cavazzini, Maria Ciccone, Giulia Daghia, Olga Sofritti, Elena Saccenti, Massimo Negrini & Gian Matteo Rigolin. (2014) Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high‐risk subgroups. Cancer Medicine 3:3, pages 555-564.
Crossref
Crossref
Nicoletta Martone, Carlo Lucioni, Silvio Mazzi & Valeria Fadda. (2014) New Oncological Drugs: Analysis of Survival Gain. Global & Regional Health Technology Assessment: Italian; Northern Europe and Spanish 1:1, pages GRHTA.2014.1235.
Crossref
Crossref
Kirsty Cuthill & Stephen Devereux. (2013) How I treat patients with relapsed chronic lymphocytic leukaemia. British Journal of Haematology 163:4, pages 423-435.
Crossref
Crossref
Keith Tolley, Catherine Goad, Yunni Yi, Penny Maroudas, Amin Haiderali & Gwilym Thompson. (2012) Utility elicitation study in the UK general public for late-stage chronic lymphocytic leukaemia. The European Journal of Health Economics 14:5, pages 749-759.
Crossref
Crossref
April D. Sorrell, Carin R. Espenschied, Julie O. Culver & Jeffrey N. Weitzel. (2013) Tumor Protein p53 (TP53) Testing and Li-Fraumeni Syndrome. Molecular Diagnosis & Therapy 17:1, pages 31-47.
Crossref
Crossref
Eleonora Fonte, Benedetta Apollonio, Lydia Scarfò, Pamela Ranghetti, Claudia Fazi, Paolo Ghia, Federico Caligaris-Cappio & Marta Muzio. (2013)
In Vitro
Sensitivity of CLL Cells to Fludarabine May Be Modulated by the Stimulation of Toll-like Receptors
. Clinical Cancer Research 19:2, pages 367-379.
Crossref
Crossref
Barbara Vannata, Idanna Innocenti, Francesco Autore, Federica Sorà, Patrizia Chiusolo, Giuseppe Leone, Simona Sica & Luca Laurenti. (2012) High-dose glucocorticoids plus Ofatumumab in fludarabine/alemtuzumab-resistant B-cell chronic lymphocytic leukemia. American Journal of Hematology 87:12, pages E133-E133.
Crossref
Crossref
Michael J Keating & Constantine TamMarina MottaAlessandra Ferrajoli. 2012. Advances in the Treatment of B-Cell Chronic Lymphocytic Leukemia. Advances in the Treatment of B-Cell Chronic Lymphocytic Leukemia
66
74
.
Marays VelizJavier Pinilla-Ibarz. (2012) Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia. Cancer Control 19:1, pages 37-53.
Crossref
Crossref
Jennifer R. Brown. (2011) The Treatment of Relapsed Refractory Chronic Lymphocytic Leukemia. Hematology 2011:1, pages 110-118.
Crossref
Crossref
William G. WierdaSwaminathan PadmanabhanGeoffrey W. ChanIra V. GuptaSteen Lisby & Anders Österborg. (2011) Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study. Blood 118:19, pages 5126-5129.
Crossref
Crossref
Issa F. Khouri, Roland Bassett, Nancy Poindexter, Susan O'Brien, Carlos E. Bueso-Ramos, Yvonne Hsu, Alessandra Ferrajoli, Michael J. Keating, Richard Champlin & Marcelo Fernandez-Vina. (2011) Nonmyeloablative allogeneic stem cell transplantation in relapsed/refractory chronic lymphocytic leukemia. Cancer 117:20, pages 4679-4688.
Crossref
Crossref
Ginah Nightingale. (2011) Ofatumumab: A Novel Anti-CD20 Monoclonal Antibody for Treatment of Refractory Chronic Lymphocytic Leukemia. Annals of Pharmacotherapy 45:10, pages 1248-1255.
Crossref
Crossref
M Hoyle, L Crathorne, R Garside & C Hyde. (2011) Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Health Technology Assessment 15:Suppl 1, pages 61-67.
Crossref
Crossref
M Hoyle, L Crathorne, R Garside & C Hyde. (2011) Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK. Health Technology Assessment 15:Suppl 1, pages 61-67.
Crossref
Crossref
Chadi NabhanNeil E. Kay. (2011) The Emerging Role of Ofatumumab in the Treatment of Chronic Lymphocytic Leukemia. Clinical Medicine Insights: Oncology 5, pages CMO.S4087.
Crossref
Crossref
Alessandra Ferrajoli. (2010) Treatment of Younger Patients with Chronic Lymphocytic Leukemia. Hematology 2010:1, pages 82-89.
Crossref
Crossref
Karen W. L. Yee & Susan M. O'Brien. 2011. Management of Hematologic Malignancies. Management of Hematologic Malignancies
81
102
.
David L. Porter, Edwin P. Alyea, Joseph H. Antin, Marcos DeLima, Eli Estey, J.H. Frederik Falkenburg, Nancy Hardy, Nicolaus Kroeger, Jose Leis, John Levine, David G. Maloney, Karl Peggs, Jacob M. Rowe, Alan S. Wayne, Sergio Giralt, Michael R. Bishop & Koen van Besien. (2010) NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation 16:11, pages 1467-1503.
Crossref
Crossref
Susan O'Brien & Anders Österborg. (2010) Ofatumumab: A New CD20 Monoclonal Antibody Therapy for B-Cell Chronic Lymphocytic Leukemia. Clinical Lymphoma Myeloma and Leukemia 10:5, pages 361-368.
Crossref
Crossref
Steven J. Lemery, Jenny Zhang, Mark D. Rothmann, Jun Yang, Justin Earp, Hong Zhao, Andrew McDougal, Anne Pilaro, Raymond Chiang, Joseph E. Gootenberg, Patricia Keegan & Richard Pazdur. (2010) U.S. Food and Drug Administration Approval: Ofatumumab for the Treatment of Patients with Chronic Lymphocytic Leukemia Refractory to Fludarabine and Alemtuzumab. Clinical Cancer Research 16:17, pages 4331-4338.
Crossref
Crossref
Mark Sanford & Paul L. McCormack. (2010) Ofatumumab. Drugs 70:8, pages 1013-1019.
Crossref
Crossref
William G. WierdaThomas J. KippsJiří MayerStephan StilgenbauerCathy D. WilliamsAndrzej HellmannTadeusz RobakRichard R. FurmanPeter HillmenMarek TrnenyMartin J.S. DyerSwami PadmanabhanMagdalena PiotrowskaTomas KozakGeoffrey ChanRandy DavisNedjad LosicJoris WilmsCharlotte A. RussellAnders Österborg. (2010) Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia. Journal of Clinical Oncology 28:10, pages 1749-1755.
Crossref
Crossref
Javier Pinilla-Ibarz & Amy Mcquary. (2010) Chronic Lymphocytic Leukemia: Putting New Treatment Options into Perspective. Cancer Control 17:2_suppl, pages 4-15.
Crossref
Crossref
Michael J. Keating, Argyris Dritselis, Uma Yasothan & Peter Kirkpatrick. (2010) Ofatumumab. Nature Reviews Drug Discovery 9:2, pages 101-102.
Crossref
Crossref
Lukáš Smolej. (2010) How I Treat Elderly or Comorbid Patients with Chronic Lymphocytic Leukemia. Acta Medica (Hradec Kralove, Czech Republic) 53:4, pages 213-220.
Crossref
Crossref
Leslie A. Andritsos, John C. Byrd & Steven M. Devine. 2010. Allogeneic Stem Cell Transplantation. Allogeneic Stem Cell Transplantation
43
52
.
Tadeusz Robak, Krzysztof Jamroziak & Pawel Robak. (2009) Current and Emerging Treatments for Chronic Lymphocytic Leukaemia. Drugs 69:17, pages 2415-2449.
Crossref
Crossref
Julio DelgadoDonald W. Milligan & Peter Dreger. (2009) Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia: ready for prime time?. Blood 114:13, pages 2581-2588.
Crossref
Crossref
Julio Delgado, Javier Briones & Jorge Sierra. (2009) Emerging therapies for patients with advanced chronic lymphocytic leukaemia. Blood Reviews 23:5, pages 217-224.
Crossref
Crossref
Marina Motta, William G. Wierda & Alessandra Ferrajoli. (2009) Chronic lymphocytic leukemia. Cancer 115:17, pages 3830-3841.
Crossref
Crossref
Tadeusz Robak. (2009) Ofatumumab for the treatment of chronic lymphocytic leukemia. Therapy 6:4, pages 577-587.
Crossref
Crossref
Apostolia-Maria Tsimberidou & Michael J. Keating. (2009) Treatment of fludarabine-refractory chronic lymphocytic leukemia. Cancer 115:13, pages 2824-2836.
Crossref
Crossref
Sonia Cunningham, Sabeeha Muneer, Sundar Jagannath, Sagar Lonial, Stefan Faderl & Stephan Stilgenbauer. (2009) The 50th Annual Meeting of the American Society of Hematology. Clinical Lymphoma and Myeloma 9:3, pages 197-205.
Crossref
Crossref
Constantine S. Tam & Issa Khouri. (2009) The role of stem cell transplantation in the management of chronic lymphocytic leukaemia. Hematological Oncology 27:2, pages 53-60.
Crossref
Crossref
Davide Rossi, Michaela Cerri, Clara Deambrogi, Elisa Sozzi, Stefania Cresta, Silvia Rasi, Lorenzo De Paoli, Valeria Spina, Valter Gattei, Daniela Capello, Francesco Forconi, Francesco Lauria & Gianluca Gaidano. (2009)
The Prognostic Value of
TP53
Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
. Clinical Cancer Research 15:3, pages 995-1004.
Crossref
Crossref
Karen Yee, Michael Keating & Susan O’Brien. 2008. Chronic Lymphocytic Leukemia. Chronic Lymphocytic Leukemia
141
164
.
Alessandra Ferrajoli, Bang-Ning Lee, Ellen J. Schlette, Susan M. O'Brien, Hui Gao, Sijin Wen, William G. Wierda, Zeev Estrov, Stefan Faderl, Evan N. Cohen, Changping Li, James M. Reuben & Michael J. Keating. (2008) Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 111:11, pages 5291-5297.
Crossref
Crossref